Unregistered Sales of
In October and November 2019, we entered
into a series of securities purchase agreements for the sale of 1,185,715 units at a $0.35 per unit sales price. Each unit consisted
of one share and one warrant to purchase a share of common stock at an exercise price of $0.50.
In November 2019, we converted $20,000
of outstanding debt due to one of our directors into 40,000 shares of common stock and $20,000 of outstanding debt due to a consultant
into 40,000 shares of common stock.
On November 20, 2019, we issued 831,481
shares to a note holder in exchange for the conversion of $415,740.82 of principal and interest on convertible notes.
On November 25, 2019, we issued 500 shares
to a director in exchange for services.
On November 25, 2019, we issued 254,442
shares to five consultants pursuant to consulting agreements.
On November 25, 2019, we issued 377,834
shares pursuant to a research collaboration and master services agreement with Chemveda Life Sciences India Private Limited.
On November 25, 2019, we issued 150,000
shares due to BioNucleonics, Inc. pursuant to a September 23, 2019 Settlement Agreement.
On December 2, 2019, we issued 503,295
shares to a note holder in exchange for the conversion of $251,674.74 of principal and interest on convertible notes.
The issuances of the securities mentioned
above qualified for the exemption from registration contained in Section 4(2) of the Securities Act of 1933.